Real-world Study of Citicoline on the Neurological Prognosis of Acute and Convalescent Patients with Ischemic Stroke

Abstract

Objective: To evaluate the effect and safety of citicoline on the improvement of neurological function in patients with ischemic stroke. Methods: The Mini-Mental State Examination (MMSE) score and National Institutes of Health Stroke Scale (NIHSS) score were analyzed in 8780 patients with ischemic stroke who received citicoline therapy from January 2023 to April 2024 at 1 month, 2 months, and 3 months after treatment. Results: With the prolongation of treatment, the MMSE and NIHSS scores of the patients improved significantly, and the total clinical effectiveness rate at three months was 43.08%. The incidence of adverse reactions was 0.14%, mainly mild gastrointestinal reactions and central nervous system reactions. Conclusion: Citicoline has a significant effect on improving neurological function in patients with ischemic stroke, and its safety is high.